Vivatides has raised $54 million in a Series A funding round, while Life Bio has attracted $80 million in investments. These fundraising efforts reflect a robust interest in biotech innovations, providing opportunities for CROs to partner in bioanalytical and CMC services. The capital influx will likely support the advancement of their respective pipelines, emphasizing the need for strategic planning and regulatory expertise to navigate the complexities of drug development.
Source: Fierce Biotech ↗